Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Derazantinib - Basilea Pharmaceutica/Merck & Co

Next Previous
Search
Drug Profile

Derazantinib - Basilea Pharmaceutica/Merck & Co

Alternative Names: AQ-14741087; ARQ-087; ARQ-087.2HCl; BAL 087; Derazantinib hydrochloride

Latest Information Update: 18 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ArQule
  • Developer Basilea Pharmaceutica; Institute for Clinical Cancer Research IKF GmbH at Krankenhaus Nordwest; Merck & Co; Peking University; Sinovant Sciences
  • Class Amines; Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Macrophage colony-stimulating factor receptor antagonists; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma
  • Phase I/II Gastric cancer; Urogenital cancer
  • Preclinical Breast cancer
  • No development reported Solid tumours

Most Recent Events

  • 06 Apr 2025 Basilea Pharmaceuticacompletes expanded access programme for Derazantinib in Cholangiocarcinoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable) (PO) (NCT04087876)
  • 28 May 2023 No recent reports of development identified for phase-0 development in Cholangiocarcinoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in China (PO, Capsule)
  • 28 May 2023 No recent reports of development identified for phase-0 development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in China (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top